Rituximab

• Efficacy and Safety of Obinutuzumab versus Rituximab in childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome : à double-bli… Recruiting
  2024-514240-93-00 Phase II/III 1 country Assistance Publique Hopitaux De Paris
• A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects with WAS. Recruiting
  2024-517792-20-00 Phase III 1 country Fondazione Telethon Ets
• Rituximab-induced remission in CIDP (ReCIX study) Recruiting
  2024-512506-25-00 Phase III 1 country Amsterdam UMC Stichting
• HOVON 170 DLBCL: ANTICIPATE: Prevention of ANThracycline-Induced Cardiac dysfunction by dexrazoxane In PATients with diffusE large B-cell ly… Recruiting
  2023-505377-32-00 Phase III 1 country Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)
• Phase III randomized, multicenter open label clinical trial to evaluate the efficacy of immunomodulatory therapy in case of psychiatric diso… Recruiting
  2024-518259-49-00 Phase III 1 country Centre Hospitalier Universitaire De Bordeaux
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting
  2023-505436-35-00 Phase III 6 countries Lysarc
• Evaluation of the efficacy and safety of Rituximab in patients with Amyotrophic Lateral Sclerosis (ALS) Recruiting
  2022-502743-35-00 Phase II 1 country Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.
• CAR-T-cell treatment for untreated high risk MANtle Cell Lymphoma Recruiting
  2022-502405-15-01 Phase II 5 countries Klinikum Der Universitat Munchen AöR
• FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab … Recruiting
  2022-501554-11-00 Phase II 1 country French Innovative Leukemia Organization
• A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting
  2022-502113-28-00 Phase III 8 countries Regeneron Pharmaceuticals Inc.
• Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-Guided Dose Reduction in Patients with Rheumatoid Arthriti… Recruiting
  2023-506638-59-01 Phase IV 1 country UZ Leuven
• A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part… Recruiting
  2022-503092-28-00 Phase III 8 countries Regeneron Pharmaceuticals Inc.
• A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory… Recruiting
  2023-503206-37-00 Phase III 4 countries F. Hoffmann-La Roche AG
• A multicenter randomized trial to evaluate the efficacy of pioglitazone to improve renal outcome in ANCA-associated vasculitis - RENATO Recruiting
  2022-501057-36-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient… Recruiting
  2022-501810-77-00 Phase III 5 countries Lysarc
• TCRaß+CD19+ depleted haploidentical stem cell transplantation followed by immunotherapy in patients with relapsed/resistant high-risk neurob… Recruiting
  2024-519089-32-02 Phase II 1 country IRCCS Istituto Giannina Gaslini
• Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line tr… Recruiting
  2024-512320-11-00 Phase III 2 countries Medical Center - University Of Freiburg
• Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients w… Recruiting
  2022-501808-96-00 Phase II 2 countries Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR
• A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting
  2022-501187-18-00 Phase III 2 countries University Of Saarland
• EvER-ILD 2: Evaluation of Efficacy and safety of Rituximab in patients with progressive Interstitial Lung Disease (ILD) with inflammatory co… Recruiting
  2022-501335-16-00 Phase II/III 1 country Centre Hospitalier Regional Universitaire De Tours
• VEMURAFENIB PLUS RITUXIMAB AS A CHEMOTHERAPY-FREE ALTERNATIVE TO CLADRIBINE FOLLOWED BY MRD-GUIDED RITUXIMAB IN FRONT-LINE HAIRY CELL LEUKEM… Recruiting
  2024-520119-41-00 Phase II 1 country Universita' Degli Studi Di Perugia
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Che… Recruiting
  2023-504264-41-00 Phase I/II 8 countries F. Hoffmann-La Roche AG
• Early Stage Follicular LymphOma and RadioTherapy PLUS anti-CD20 Antibody Recruiting
  2023-509278-41-00 Phase III 1 country Universitaetsklinikum Heidelberg AöR
• A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-C… Recruiting
  2022-502646-27-00 Phase II/III 5 countries Merck Sharp & Dohme LLC

Showing 73–96 of 193 trials